EGFR and breast cancer: ISGylation can induce cancer progression by the modulation of several signalling pathways, such as epidermal growth factor receptor (EGFR) recycling, Ki-Ras, and Akt in breast cancer, suggesting a potential therapeutic avenue by inhibiting ISGylation to reverse the malignant condition of these cells [50].